SMART-101 is under clinical development by Smart Immune and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SMART-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SMART-101 is under development for the treatment of acute lymphocytic leukemia, acute myeloid leukemia, relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome and for use in hematopoietic stem cell transplantation. The therapeutic candidate is developed based on ex vivo thymus platform that differentiates CD34 positive stem cells purified from cord blood or peripheral hematopoietic stem cells into T Cell Progenitors so-called ProTcell. It is administered through parenteral route.
For a complete picture of SMART-101’s drug-specific PTSR and LoA scores, buy the report here.